WILLIAM S. REARDON, C.P.A.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

MADRIGAL PHARMACEUTICALS, INC.

Filing Date Source Excerpt
2008-04-29 Mr. Reardon received both his undergraduate degree in East Asian history and his M.B.A. from Harvard University.
2009-04-30 Mr. Reardon was a business assurance (audit) partner at PricewaterhouseCoopers LLP and leader of its life sciences industry practice.
2010-04-30 Mr. Reardon received both his undergraduate degree in East Asian history and his M.B.A. from Harvard University. Our Board of Directors has concluded that Mr. Reardon should serve as a director as of the date of this proxy statement because of his extensive expertise in accounting and financial matters and his experience in analyzing and evaluating financial statements as a former auditor, in particular in the biopharmaceutical industry.
2011-04-29 Mr. Reardon was a business assurance (audit) partner at PricewaterhouseCoopers LLP and leader of its life sciences industry practice.
2012-04-27 Mr. Reardon was a business assurance (audit) partner at PricewaterhouseCoopers LLP and has expertise in accounting and financial matters.
2013-04-29 Mr. Reardon received both his undergraduate degree in East Asian history and his M.B.A. from Harvard University. Our Board of Directors has concluded that Mr. Reardon should serve as a director as of the date of this proxy statement because of his extensive expertise in accounting and financial matters and his experience in analyzing and evaluating financial statements as a former auditor, in particular in the biopharmaceutical industry.
2014-04-30 Until his retirement in 2002 from PricewaterhouseCoopers LLP, an international accounting firm, where he was employed from June 1973 to July 2002, Mr. Reardon was a business assurance (audit) partner at the firm's Boston office and leader of its life sciences industry practice for New England and the eastern United States.
2015-04-30 Mr. Reardon received both his undergraduate degree in East Asian history and his M.B.A. from Harvard University. Our Board of Directors has concluded that Mr. Reardon should serve as a director as of the date of this proxy statement because of his extensive expertise in accounting and financial matters and his experience in analyzing and evaluating financial statements as a former auditor, in particular in the biopharmaceutical industry.

Data sourced from SEC filings. Last updated: 2026-02-03